Welcome to our dedicated page for Optinose news (Ticker: OPTN), a resource for investors and traders seeking the latest updates and insights on Optinose stock.
Optinose, Inc. (NASDAQ: OPTN) is a specialty pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. News related to Optinose often centers on its commercial product XHANCE, financial performance, clinical data, and corporate developments. The company reports net product revenue from sales of XHANCE and provides regular updates on prescription trends, including new prescriptions and total prescriptions, as well as commentary on inflection points in demand.
Investors and observers following OPTN news can expect recurring announcements of quarterly and full-year financial results, including net revenue from XHANCE, operating expenses, income or loss from operations, and balance sheet data such as cash and cash equivalents. Optinose also issues guidance on expected net revenue, average net revenue per prescription, and operating expenses, and may update this guidance based on evolving business conditions.
Beyond financial updates, Optinose news includes clinical and scientific developments. The company has highlighted peer-reviewed publications describing the efficacy of XHANCE, including randomized controlled trials in chronic rhinosinusitis patients with or without prior sinus surgery. These communications discuss outcomes such as symptom improvement, sinus opacification, and quality of life.
Corporate and capital markets news for OPTN includes announcements such as a 1-for-15 reverse stock split intended to help regain compliance with Nasdaq’s minimum bid price requirement, as well as leadership changes and appointments. Optinose has also announced that it has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and customary closing conditions. For those tracking OPTN, the news flow provides insight into the company’s commercial trajectory, financial condition, clinical positioning of XHANCE, and potential future corporate structure.
Optinose (NASDAQ:OPTN), a pharmaceutical company specializing in treatments for ear, nose, and throat (ENT) and allergy patients, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's management team will deliver a presentation on September 9, 2024, at 10:00 a.m. ET, providing a comprehensive overview of the company and updates on its business operations.
Investors and interested parties can access a live webcast of the presentation through the Investors page on the Optinose website. For those unable to attend the live event, a replay of the webcast will be available for 30 days following the conference.
Optinose (NASDAQ:OPTN) reported Q2 2024 financial results, with XHANCE net revenue of $20.5 million, a 5% increase from Q2 2023. The company narrowed its full-year 2024 XHANCE net revenue guidance to $85.0-$90.0 million and increased expected average net revenue per prescription to at least $250. Notably, XHANCE was added to Express Scripts' national formularies, covering over 24 million lives. Optinose completed a $55 million registered direct offering, extending its cash runway through 2025. The company reported a net loss of $7.6 million for Q2 2024. Optinose continues to focus on its new first-and-only label indication for chronic sinusitis, which expands its total addressable market.
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on ear, nose and throat (ENT) and allergy treatments, has announced its plans to report second quarter 2024 financial results and corporate updates. The company will release this information before market open on Thursday, August 8, 2024. Following the release, Optinose will host a conference call and webcast at 8:00 a.m. Eastern Time on the same day.
Investors and interested parties can access the live webcast through the Investors section of Optinose's website. For those wishing to participate via telephone, pre-registration is required. A replay of the webcast will be available on the company's website for 60 days after the event.
Optinose (NASDAQ: OPTN) has announced the addition of their drug XHANCE® (fluticasone propionate) to Express Scripts' national formularies, including National Preferred, Flex, and Basic. This inclusion potentially increases access for over 24 million people. XHANCE is unique as the only medication approved for treating chronic rhinosinusitis without nasal polyps. CEO Ramy Mahmoud emphasizes the recent FDA approval and landmark studies highlighting XHANCE's effectiveness. Chronic sinusitis affects around 30 million adults in the U.S., making this expansion significant for patient treatment options.
Optinose (NASDAQ: OPTN), a pharmaceutical company specializing in treatments for ENT and allergy patients, will present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ.
The presentation, scheduled for May 20, 2024, at 11:30 a.m. ET, will feature a company overview and business update from Optinose's management team.
The live presentation will be webcast, and a replay will be available for 30 days on the Optinose website.
Optinose (NASDAQ:OPTN) reported Q1 2024 net revenue of $14.9 million for XHANCE, marking a 26% increase from Q1 2023. The company forecasts full-year 2024 XHANCE net revenues between $85-$95 million, with peak revenue expectations of at least $300 million. Optinose anticipates positive GAAP income for 2025. In March 2024, the FDA approved XHANCE for chronic rhinosinusitis without nasal polyps, significantly expanding its market. The approval of a second manufacturing site and a $55 million direct offering were also highlighted. Despite these advancements, Q1 2024 saw a net loss of $14.1 million, and operating expenses are projected between $95-$101 million for 2024.
Optinose, a pharmaceutical company specializing in ENT and allergy treatments, will announce its first quarter 2024 financial results on May 14, 2024. The company will host a conference call to discuss the results and corporate updates.
Optinose, a pharmaceutical company specializing in ENT and allergy treatments, announced a $55 million registered direct offering. The offering, led by Nantahala Capital and The D. E. Shaw Group, aims to fund operations through 2025. With a post-offering cash balance of approximately $100 million, the company expects XHANCE net revenues to range between $85 to $95 million for the full year 2024.
Summary not available.
Summary not available.